Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.

Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.

Item

http://www.wikidata.org/entity/Q47613511

Q47613511

about

Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.

Item

http://www.wikidata.org/entity/Q47613511

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Eligibility for PCSK9 Inhibito ...... fter Acute Coronary Syndromes.

@en

Eligibility for PCSK9 Inhibitors According to American College of Cardiology

@nl

type

Item

label

Eligibility for PCSK9 Inhibito ...... fter Acute Coronary Syndromes.

@en

Eligibility for PCSK9 Inhibitors According to American College of Cardiology

@nl

prefLabel

Eligibility for PCSK9 Inhibito ...... fter Acute Coronary Syndromes.

@en

Eligibility for PCSK9 Inhibitors According to American College of Cardiology

@nl

P1476

Eligibility for PCSK9 Inhibito ...... fter Acute Coronary Syndromes.

@en

P2093

Alexios Karagiannis

http://www.w3.org/2001/XMLSchema#string

Baris Gencer

http://www.w3.org/2001/XMLSchema#string

Christian M Matter

http://www.w3.org/2001/XMLSchema#string

David Carballo

http://www.w3.org/2001/XMLSchema#string

David Nanchen

http://www.w3.org/2001/XMLSchema#string

Dik Heg

http://www.w3.org/2001/XMLSchema#string

François Mach

http://www.w3.org/2001/XMLSchema#string

Konstantinos C Koskinas

http://www.w3.org/2001/XMLSchema#string

Nicolas Rodondi

http://www.w3.org/2001/XMLSchema#string

Reto Auer

http://www.w3.org/2001/XMLSchema#string

P2860

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.

Identifying familial hypercholesterolemia in acute coronary syndrome.

P31

scholarly article

P356

10.1161/JAHA.117.006537

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Lüscher

Stephan Windecker

Lorenz Räber

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29122809

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

5721754

http://www.w3.org/2001/XMLSchema#string

Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.

about

Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921

P932